在基代谢物D-2-基酸依赖的代谢重编程诱导肌缩在癌症缓解症期间
Xinting Zhu1, Juan Hao2, Hong Zhang1
1Department of Pharmacy, Shanghai Sixth People's Hospital affiliated Shanghai Jiao Tong University School of Medicine, 600 Yishan Road, Shanghai, 200233, China.
异酸脱酶1 (IDH1) 中的遗传突变通过增加D-2-基酸盐 (D2HG) 水平来加速癌症缓解症,从而导致肌肉消耗. IDH1抑制剂在治疗这种疾病方面表现有前途.
科学领域:
- 在瘤学瘤学.
- 代谢过程中的代谢.
- 分子生物学分子生物学
背景情况:
- 癌症缓解症涉及由于新陈代谢改变而导致的肌肉消耗.
- 由遗传突变驱动的代谢重编程与缓解症的进展有关.
研究的目的:
- 为了研究基因突变和代谢重编程在癌症缓解症中的作用.
- 为了确定有助于肌肉缩的特定代谢物.
主要方法:
- 查代谢物和评估它们对肌肉细胞的影响.
- 对异酸脱酶1 (IDH1) 突变患者和体内小鼠模型的分析.
- 转录基因和代谢基因分析.
- 使用IDH1抑制剂治疗ivosidenib.
主要成果:
- D-2-基质酸盐 (D2HG) 治疗减少了肌管宽度,并增加了E3无素连接酶.
- 在IDH1突变患者中,D2HG水平较高.
- 突变的IDH1在小鼠中加速了缓冲症和恶化了生存率.
- 在临床前的模型中,IVOSIDENIB治疗延迟了缓解症的进展.
结论:
- 通过IDH1突变介导的D2HG积累有助于癌症缓解症的进展.
- 针对IDH1突变提供了潜在的个性化治疗策略,用于癌症缓存症.
更多相关视频
06:51Utilizing 18F-FDG PET/CT Imaging and Quantitative Histology to Measure Dynamic Changes in the Glucose Metabolism in Mouse Models of Lung Cancer
Published on: July 21, 2018
06:32Intra-Cardiac Injection of Human Prostate Cancer Cells to Create a Bone Metastasis Xenograft Mouse Model
Published on: November 4, 2022
相关概念视频
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...
mTOR Signaling and Cancer Progression
The mTOR pathway or the...
Overview of Protein Metabolism
Amino acids play various roles in the body once they are absorbed into cells. They are restructured...
Electron Transport Chain: Complex I and II
ROS generation is regulated and maintained at moderate levels necessary...
Targeted Cancer Therapies
There are several types of targeted therapies against...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
